Biocon Ltd, in collaboration with its European partner Zentiva, has obtained decentralised procedure approval in the European Union for their complex formulation, Liraglutide, which is used to manage diabetes and support weight management.
The approval covers generic versions of Victoza, indicated for treating Type-2 Diabetes, and Saxenda, used for weight management, Biocon Ltd stated in a regulatory filing.
Victoza and Saxenda are trademarks owned by Novo Nordisk.
May 2026 - India’s electric vehicle (EV) market is witnessing a sharp surge in demand, driven largely by rising fuel prices and shifting consumer preferences, but manufacturers are struggling to keep up...
Global oil prices climbed sharply following renewed U.S. military strikes on Iranian targets, intensifying geopolitical tensions and raising fresh concerns over energy supply disruptions. According to multiple market reports, crude prices rose...
May 2026: A key parliamentary panel is set to examine the growing impact of the ongoing West Asia crisis on India’s maritime trade, as concerns deepen over supply chain disruptions, rising freight...
What began as an offhand remark has rapidly evolved into one of India’s most unexpected digital-political phenomena. The “Cockroach Janta Party” (CJP), a satirical online movement, has captured national attention, reflecting a...
Industry Insights Magazine delivers expert analysis, trends, and startup stories across sectors like Finance, Healthcare, Manufacturing, and Real Estate. With curated interviews, case studies, and reports, we empower professionals and entrepreneurs with actionable insights, helping them navigate change, discover opportunities, and lead confidently in today’s dynamic business landscape.
Discussion about this post